Navigation Links
Malaria May Gain Resistance To Single Drug Prescriptions

Pharmaceutical companies have been called upon to stop marketing a single treatment malarial drug, by the World Health Organization (WHO), as the parasite which causes malaria may develop a resistance to it. //

Arata Kochi, director of the WHO's malaria department, said that the practice of using artemisinin, one of the most effective anti-malarials, on its own would result in the parasite becoming resistant to the drug, and will have disastrous consequences for malaria treatment.

Kochi added that the WHO feared that using artemisinin as a single drug would lead to it going the same way as other anti-malarial drugs such as chloroquine, sulphadoxine-pyrimethamine and atovaquone which lost their effectiveness because the malarial parasite was able to develop resistance to these drugs.

‘If we lose artemisinin, we will no longer have an effective cure for malaria. We cannot afford to repeat mistakes from the past,’ Nature quoted Kochi, saying. Artemisinin combination therapies are currently the single most effective treatment to cure malaria, with a 95% cure rate.

Edited (ANI)
'"/>




Page: 1

Related medicine news :

1. Malaria strikes Munger tribals
2. Sponging Cattle betters spraying in eradicating Malaria
3. Gene researchers make Malaria-resistant mosquito
4. More Treatment Options For Malaria
5. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
6. Jharkhand reports 13,000 Malaria cases
7. Researchers Discover Protein That Causes Malaria
8. Malarial gene ascertained
9. Artesunate Is Better For Malaria Than Quinine
10. New Strategies For Effective Treatment Of Malaria
11. Chloroquine and Primaquine combination Malarial drug for resistant parasites.

Post Your Comments:
(Date:11/30/2009)... , CARDIFF, Calif., Nov. 30 /PRNewswire-FirstC....jedimindinc.com) is pleased to announce the Compa... available for purchase. The game, "Think-Tac-Toe"...o play the game with the power of their mind and i... be sold online at a price of $49 and can be purch...
(Date:11/30/2009)..., CHARLTON, Mass., Nov. 30 Harrin...ce the addition of Family Practice physicians Mart... Mathur to its Charlton practice. ,, These fo... coming from the Fallon Clinic, will soon join the...e at Charlton medical office building under constr...
(Date:11/30/2009)... , MINNEAPOLIS, Nov. 30 Th...octor , is now required equipment in the Top Fuel,... classes of the National Hot Rod Association (NHRA... Top Alcohol dragster and Top Alcohol Funny Car dr...ject is the only product that allows medical care...
(Date:11/30/2009)...nearly two years of development and extensive disc...for Quality and Efficiency in Health Care (IQWiG) ...etween cost and benefit. The Institute can now app...ns awarded by the Federal Joint Committee (G-BA). ...ing on recommendations to the GKV-Spitzenverband [...
(Date:11/30/2009)...studies report safe transplant results in animals ...- Two new studies in animals suggest that stem cel...blood could help treat some lung and heart disorde...ells can differentiate into a long list of differe...Park of the Samsung Medical Center in Seoul, Korea...
Breaking Medicine News(10 mins):Health News:First Thought-Controlled Game Complete From Jedi Mind, Inc. 2Health News:Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton 2Health News:Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton 3Health News:National Hot Rod Association Mandates Eject Helmet Removal System for 2010 2Health News:IQWiG presents a method for evaluating the relation between cost and benefit 2Health News:IQWiG presents a method for evaluating the relation between cost and benefit 3Health News:IQWiG presents a method for evaluating the relation between cost and benefit 4Health News:IQWiG presents a method for evaluating the relation between cost and benefit 5
... PALM BEACH, Fla., March 11 The Smart Circle,Inte...rketing and,direct-to- consumer sales, together wi...er the first-ever National Massage Network., The ...tates., Thomas Edison once stated, "The doctor of...
...H SAN FRANCISCO, Calif., March 11 Cell,Genesys, I.... Tetlow, senior,vice president and chief financia...update on Tuesday, March 18 at 8:00 a.m. ET at the...s, will,present a company update on March 18 at 10...
...archers offer a new way to detect and treat autism...en the brain is most responsive., GAINESVILLE, Fl...er autism is diagnosed and therapy begun, the grea... their,diagnosis of this disorder on social intera...
...res, parent company, Medical Mutual of Ohio to ben...costs, improved customer service, CLEVELAND, Marc...ument and process management software solution, ha...edical Mutual,of Ohio (MMO)., (Logo: http://www....
...ate Dental Van to Provide Students with Free Denta...Oral Health Education, SAN FRANCISCO, March 11 A...intaining good oral health habits drew smiles from...,event, which was hosted by Critics Choice Award W...
...d-Renowned Stem Cell Researcher is First to Adopt ...roduct, FREMONT, Calif., March 11 WaferGen,Biosy...developer of,state-of-the-art gene expression, gen...ring in its SmartSlide product,line. The SmartSlid...
Other Medicine News:Health News:Smart Circle International, LLC Launches Its National Health and Wellness Network Complimentary 1/2-Hour Massage for Everyone 2Health News:Cell Genesys to Present at the Cowen and Company and the Lehman Brothers Healthcare Investor Conferences 2Health News:Autism Awareness Month - New Hope for Detecting/Reversing Autism in Infants 2Health News:Antares Management Solutions Selects Hyland Software's OnBase 2Health News:'Hairspray's' Nikki Blonsky Joins Colgate-Palmolive and San Francisco Elementary School Students for Bright Smiles Comedy Showcase 2Health News:'Hairspray's' Nikki Blonsky Joins Colgate-Palmolive and San Francisco Elementary School Students for Bright Smiles Comedy Showcase 3Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 2Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 3Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 4Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 5Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 6
(Date:11/30/2009)..., Nov. 30 Minimally-invasive proce...surgery, particularly in oncology, cardiology and ... for image-guided navigation expected to reach $60...vantages offered by minimally-invasive procedures,... patient comfort and faster patient throughput. ...
(Date:11/30/2009)...AM, Mass., Nov. 30 Decision Resour...ory firms focusing on pharmaceutical and healthcar...g market in Russia will grow nine percent annually...million by 2013. This growth will be driven mainly...d increased use of more-expensive therapies like p...
(Date:11/30/2009)...IANAPOLIS, Nov. 30 The U...d Cymbalta® (duloxetine HCl) for the maintena...) in adults, Eli Lilly and Company (NYSE: LLY ) ...disorder can be a chronic illness, it is important...option that is effective in both the acute and mai...
Breaking Medicine Technology:Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 2Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 3Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 4Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 5Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 2FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 4FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 5BD Announces Results for Third Fiscal Quarter 53187 1BD Announces Results for Third Fiscal Quarter 53187 2BD Announces Results for Third Fiscal Quarter 53187 3BD Announces Results for Third Fiscal Quarter 53187 4BD Announces Results for Third Fiscal Quarter 53187 5BD Announces Results for Third Fiscal Quarter 53187 6BD Announces Results for Third Fiscal Quarter 53187 7BD Announces Results for Third Fiscal Quarter 53187 8BD Announces Results for Third Fiscal Quarter 53187 9BD Announces Results for Third Fiscal Quarter 53187 10BD Announces Results for Third Fiscal Quarter 53187 11BD Announces Results for Third Fiscal Quarter 53187 12BD Announces Results for Third Fiscal Quarter 53187 13BD Announces Results for Third Fiscal Quarter 53187 14BD Announces Results for Third Fiscal Quarter 53187 15BD Announces Results for Third Fiscal Quarter 53187 16BD Announces Results for Third Fiscal Quarter 53187 17BD Announces Results for Third Fiscal Quarter 53187 18BD Announces Results for Third Fiscal Quarter 53187 19BD Announces Results for Third Fiscal Quarter 53187 20BD Announces Results for Third Fiscal Quarter 53187 21BD Announces Results for Third Fiscal Quarter 53187 22BD Announces Results for Third Fiscal Quarter 53187 23BD Announces Results for Third Fiscal Quarter 53187 24BD Announces Results for Third Fiscal Quarter 53187 25BD Announces Results for Third Fiscal Quarter 53187 26BD Announces Results for Third Fiscal Quarter 53187 27BD Announces Results for Third Fiscal Quarter 53187 28Wolters Kluwer Health Launches Interactive Platform for Pharmacology Journal Content 53186 1Wolters Kluwer Health Launches Interactive Platform for Pharmacology Journal Content 53186 2Wolters Kluwer Health Launches Interactive Platform for Pharmacology Journal Content 53186 3Wolters Kluwer Health Launches Interactive Platform for Pharmacology Journal Content 53186 4Obama White House Can Save 243 7 Trillion and Extend Lifespan 29+ Years Predicts Revolutionary A4M Healthcare Plan 53184 1Obama White House Can Save 243 7 Trillion and Extend Lifespan 29+ Years Predicts Revolutionary A4M Healthcare Plan 53184 2
...CI CORPORATION,(Amex: CVM ) announced today that ...eatured presenter at the International Society for... BioShowcase in,Gaithersburg Maryland. Mr. Kersten...Small Biotechnology Company" today at 3:15 p.m. (E...pleted a $15 million private placement of,common s...
...I Study in Previous Nonresponders also Reported, ...tion (NYSE: SGP ) today provided an update on the...investigational oral hepatitis C,protease inhibito...in,treatment-naive (previously untreated) hepatiti...bination with PEGINTRON(TM) (peginterferon,alfa-2b...
Other Medicine Technology:CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase 2Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 2Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 4Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 5Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 6Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 7Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 8Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 9
Arm Support Sleeves
Compression Arm Sleeves Bolero
Sub Pectoral Bra
Bandeau Bra
Medicine Products: